Lilly Deutschland Gmbh

Name

Lilly Deutschland Gmbh

Legal name

Lilly Deutschland GmbH

Website

https://lilly-pharma.de

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Lilly Deutschland GmbH is the German subsidiary of Eli Lilly and Company, developing, marketing, and distributing prescription pharmaceuticals across diabetes, oncology, obesity, immunology, and other therapy areas in Germany via pharmacy and wholesale channels, with a major new manufacturing facility under construction in Alzey.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Pharmaceutical products
• Diabetes therapies
• Oncology treatments
• Obesity therapeutics
• Patient support services

Headquarters

HQ city

Bad Homburg

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Distribution channels2 records

Marketing channels4 records

Core offering

Lilly Deutschland GmbH develops, markets, and distributes prescription pharmaceutical products in Germany across multiple therapeutic areas including diabetology, oncology, obesity (Adipositas), immunology, neurodegenerative diseases, dermatology, gastroenterology, neurology, osteology, and rheumatology. The company also operates the LillyPlus Patientenservice, a patient support and information platform, and runs clinical research operations in Germany. A new manufacturing facility in Alzey is being built to supply injectable and other pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Products and services

• LillyPlus Patientenservice

Segments10 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Broad incumbents

• Eli Lilly and Company: The US parent company of Lilly Deutschland GmbH and the global originator of the entire product portfolio distributed by the German subsidiary. It is the most direct comparator given that all of Lilly Deutschland's activities are an extension of Eli Lilly's branded pharmaceutical franchise.
• Bayer Pharma: Major German-headquartered pharmaceutical company with deep presence in cardiovascular, oncology, and women's health. It is a broad incumbent competitor with manufacturing, distribution, and clinical operations comparable to Lilly Deutschland's footprint.
• Merck Healthcare Deutschland: German pharmaceutical operations of Merck KGaA, focused on oncology, neurology, and immunology. Therapeutic area overlap with Lilly Deutschland in oncology, neurology, and immunology segments makes it a comparable peer for portfolio and market dynamics.
• AstraZeneca Deutschland: German subsidiary of UK-headquartered AstraZeneca, with significant oncology, cardiovascular, and respiratory franchises. Comparable to Lilly Deutschland in operating model, multi-therapeutic area coverage, and market access dynamics in the German pharmaceutical market.
• Boehringer Ingelheim: Major German pharmaceutical company with operations across cardiometabolic, respiratory, and immunology therapeutic areas. As a German-headquartered peer with comparable therapeutic area focus, it is a relevant comparison point for the subsidiary's market position.
• Pfizer Deutschland: German subsidiary of global pharmaceutical leader Pfizer, operating with similar scope: branded pharmaceutical distribution, clinical research, and multi-therapeutic area portfolio. It is a direct comparator for the Lilly Deutschland operating model in the German market.
• Sanofi-Aventis Deutschland: German arm of French pharmaceutical major Sanofi, with significant presence in diabetes (Lantus/Toujeo), immunology (Dupixent), and rare diseases. Direct therapeutic overlap with Lilly Deutschland in diabetes and immunology plus similar German distribution operations.
• Roche Deutschland: German subsidiary of Swiss pharmaceutical leader Roche, with strong oncology, immunology, and neurology presence. Therapeutic area overlap (oncology and immunology are primary Lilly Deutschland segments) and similar operating model make it a closely comparable peer.
• AbbVie Deutschland: German subsidiary of AbbVie, focused on immunology, oncology, and neuroscience. Direct therapeutic area overlap with Lilly Deutschland in immunology and oncology, with similar patient-service infrastructure and specialty care orientation.

Direct peers

• Novo Nordisk: Global diabetes and obesity care leader with a major German commercial presence, directly competing with Lilly Deutschland in the cardiometabolic space through the Ozempic and Wegovy franchises. It is the principal therapeutic-area competitor in Germany.

Market position

Customer concentration

• LinkedInlinkedin.com/company/lilly-deutschland-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lilly Deutschland Gmbh